Proteomics and Biomarkers
Research in our laboratory centers on the identification of biosignatures for psychiatric disorders and the response towards antidepressant drugs. Sensitive, high-throughput proteomics and metabolomics platforms are used for data generation providing a rich source for in silico pathway analyses. Our ultimate goal is to complement imprecise DSM-based clinical parameters with molecular biosignatures to improve patient diagnosis, stratification and treatment. Towards this objective we collaborate with clinician scientists at our Institute and elsewhere exploring and mining a variety of specimen sources for biomarkers.